Staff Picks /Features

The bone marrow mesenchymal stem cell: exploring its role in MGUS and multiple myeloma

Multiple myeloma (MM) is an incurable malignant disease of plasma cells, representing the most severe form of paraproteinaemia. In most…

TIDEL II trial: uncovering the predictive value of ABCB1 in determining the long-term response to imatinib in CML patients

Adelaide researchers based at the South Australian Health and Medical Research Institute (SAHMRI) have demonstrated the significance of early increases…

Educational /Features

Sponsored feature

The Evolution of Chemotherapy: using the A-DAC principle to unlock new treatment options in Hodgkin lymphoma On the 23rd of…

Biosimiliars

Can the dream of affordable cancer care come true?

Sponsored Feature

UNITY clinical trials: TGR-1202 shows promise in CLL and DLBCL TGR-1202 is a novel PI3K inhibitor currently being tested in…

Sponsored Feature

Zydelig®▼ (idelalisib): updated advice following conclusion of a safety review     Julian Cole, MA, MRCPI, Dip Pharm Med, FFPM,…

Sponsored Feature

EHA 2016 satellite symposium ‘Optimizing treatment for patients with CP-CML and Ph+ ALL’ The 2016 European Hematology Association (EHA) Annual…

Most Recent /Features

Innovative Medicines Initiative approves €40 million HARMONY project for better care of patients with hematologic malignancies

The Innovative Medicines Initiative (IMI) has approved HARMONY, a project that aims to foster better access and care for patients…

The bone marrow mesenchymal stem cell: exploring its role in MGUS and multiple myeloma

Multiple myeloma (MM) is an incurable malignant disease of plasma cells, representing the most severe form of paraproteinaemia. In most…

TIDEL II trial: uncovering the predictive value of ABCB1 in determining the long-term response to imatinib in CML patients

Adelaide researchers based at the South Australian Health and Medical Research Institute (SAHMRI) have demonstrated the significance of early increases…

ASCO/EHA 2016: Combination therapies change the standard of care in multiple myeloma

As usual, the ASCO Annual Meeting and the EHA Annual Congress were a hub of activity, data and discussion. We…

Positive Phase III results for plitidepsin

Plitidepsin (also known as dehydrodidemnin B) is a first-in-class drug originally obtained from the sea squirt Aplidium albicans.[1] Plitidepsin specifically…

Solving the CARD11 puzzle and gaining a deeper understanding of oncogenic mutations

CARD11 is a scaffold protein that is critical for antigen receptor signaling. Normally, it is locked in an “off” position…